Acromegaly is a hormonal condition caused by excessive growth hormone (GH) release. Adults are affected. Acromegaly is usually caused by a pituitary tumor. Acromegaly refers to the growth of the hands and feet. Gigantism is also a hormonal disorder characterized by excessive growth hormone release and production during childhood. Overgrowth of the bones and excessive height are common symptoms of this condition. Acromegaly and gigantism are both considered dangerous disorders that can be fatal. Both Gigantism and Acromegaly are pituitary gland illnesses with aberrant hormone releases. To address these illnesses, a variety of therapeutic options are available, including medications, surgery, and radiation therapy. The key market drivers for Acromegaly and Gigantism Treatment Market are an increase in the incidence of chronic diseases as well as an increase in the number of hormonal abnormalities.This growth is primarily driven by Rising Prevalence of Chronic Diseases, Increasing Various Hormonal Disorders and Rise in Awareness Among People About Diagnosis of the Disease.
Globally, a noticeable market trend is evident Growing Popularity of Drugs Over Surgeries. Major Players, such as Pfizer Inc (United States), Novartis AG (Switzerland), Chiasma Inc (United States), Ipsen Pharma (France), Johnson and Johnson (United States), F. Hoffmann -La Roche Ltd (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Zydus Pharmaceuticals (United States), Peptron (South Korea) and Hikma Pharmaceuticals PLC (United Kingdom) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.
June 2020- The US Food and Drug Administration (FDA) has approved oral octreotide (Mycapssa, Chiasma) delayed-release capsules for the long-term maintenance treatment of patients with acromegaly
- Rising Prevalence of Chronic Diseases
- Increasing Various Hormonal Disorders
- Rise in Awareness Among People About Diagnosis of the Disease
- Growing Popularity of Drugs Over Surgeries
- Side Effects of Certain Drugs
Increased Investment on R&D in Development of New Drugs and Technological Advancements
Stringent Regulatory Drug Approvals
AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.
Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
Against this Challenging Backdrop, Acromegaly and Gigantism Drugs Study Sheds Light on
— The Acromegaly and Gigantism Drugs Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Acromegaly and Gigantism Drugs industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Acromegaly and Gigantism Drugs industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.